Outcomes of venetoclax combined with homoharringtonine and cytarabine in fit adults patients with de novo adverse‐risk acute myeloid leukaemia: A single‐centre retrospective analysis
Bao‐Quan Song,
Xin Kong,
Yan Pu,
Yin Liu,
Jian Zhang,
De‐Pei Wu,
Hui‐Ying Qiu
Affiliations
Bao‐Quan Song
National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China
Xin Kong
National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China
Yan Pu
National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China
Yin Liu
National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China
Jian Zhang
National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China
De‐Pei Wu
National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China
Hui‐Ying Qiu
National Clinical Research Center for Hematologic Diseases Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China
Abstract Adverse‐risk acute myeloid leukemia (AML) has a dismal prognosis. We aimed to investigate the activity and tolerability of venetoclax combined with homoharringtonine (HHT) plus cytarabine (VHA) regimen for de novo adverse‐risk AML. Thirteen de novo AML patients with adverse‐risk factors were treated with venetoclax (100 mg day 1, 200 mg day 2, 400 mg days 3‐21), HHT (1 mg/m2 days 1‐5) and cytarabine (100 mg/m2 days 1‐5) (VHA regimen). Complete remission (CR) was achieved in 11/13 patient (84.6%), all of CR responders were measurable residual disease (MRD) negative detected by multi‐parameter flow cytometry (MFC). Grade 3‐4 neutropenia, anaemia, and thrombocytopenia occurred in most patients. Grade 3‐4 non haematological adverse events (AEs) included febrile neutropenia (4/13, 30.8%). With a median follow‐up of 10 months (range 4‐19), median overall survival and event‐free survival were not reached. VHA may be a promising and well‐tolerated regimen in de novo adverse‐risk AML.
